An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation

Table 1 Baseline characteristics (n = 30)

Characteristics	Value
Gender (M:F), n	23:07
Age (years), median (range)	56 (38-70)
Genotype 1, n (%)	23 (77)
Overweight, n (%)	22 (73)
Diabetes Mellitus, n (%)	18 (60)
Months from Liver Transplant, median (range)	40.5 (2-132)
High HCV RNA, n (%)	17 (57)
Cirrhosis, n (%)	3 (10)

M: Male; F: Female. Overweight: Body mass index > 25 kg/m²; High HCV RNA > 800 000 IU/mL.

Table 2 Comparison between SVR and Non-SVR groups

Variable	SVR	Non-SVR	P-value
Number of patients	18	12
Age, median (range)	55(38-67)	59 (48-70)
M: F, n	13 : 5	9 : 3
Overweight, n	14	8	0.396
Diabetes Mell-itus, n	12	6	0.296
Months from LT, median (range) High HCV RNA, n CMV anti- body positive, n Genotype 1: non 1, n Pre-Treatment biopsy, n Stage 0-1 Stage 2-3 Stage 4 Grade 0-1 Grade 2-3 Grade 4 Total weeks of treatment, median (range) Erythropoietin use, n (%) G-CSF use, n (%)	60 (4-116) 10 13 13 : 5 3 12 3 1 16 1 56 (13-84) 17 (94) 10 (56)	26 (2-132) 7 8 10 : 2 5 7 0 2 10 0 44.5 (2-60) 6 (50) 2 (17)	0.590 0.528 0.403 0.009 0.038

M: Male; F: Female; LT: Liver Transplantation; G-CSF: Granulocyte-colony stimulating factors; SVR: sunstianed virological response. Overweight: Body mass index > 25 kg/m²; High HCV RNA: > 800 000 IU/mL.